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98 Poster Session I110 (median age, 42, range; 18–75) were not. The two groups were
comparable with respect to age, gender, diagnosis, conditioning
regimens, number of TNCs infused, number of bags infused, total
volume infused, amount of DMSO and infusion rate. Patients re-
ceiving popsickle with strawberry aroma had significantly less nau-
sea (21.8% vs 6.6%, p 5 0.03) and had a trend for less vomiting
(13.6% vs 4.4%, p 5 0.1). Other infusion-related adverse events
were as follows; abdominal cramping, tachycardia, hypertension,
hypotension, chills, fever, sore throat and dyspnea. Incidences of
each of these adverse events were less than 3% in both groups and
were comparable. Conclusions: The use of popsickle with straw-
berry aroma during infusion of cryopreserved autologous PBSCs
significantly decreases infusion-related nausea, decreases vomiting
and recommended in this setting.
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DAPTOMYCIN PLUS CEFEPIME FOR MODERATE AND HIGH-RISK FE-
BRILE NEUTROPENIC PATIENTS WITH INCREASED RISK OF GRAM-POS-
ITIVE INFECTION
Rossetti, J.M., Thatikonda, C., Shadduck, R.K., Sahovic, E.,
Kaplan, R.B., Kennedy, M., Lister, J. Western Pennsylvania Cancer In-
stitute, Pittsburgh, PA.
Introduction: Febrile neutropenia following high dose chemo-
therapy or transplantation generally requires in-patient antimicro-
bial therapy. This vulnerable group of patients often has
indwelling catheters, which increase the risk of certain pathogens.
A focus of infection may not be clear, supporting the use of
a broad-spectrum regimen. As gram-positive bacteria are a leading
cause of infections in febrile neutropenic patients, vancomycin is
commonly used in the initial treatment regimen. The rising inci-
dence of vancomycin-resistance in many transplant units has
prompted the investigation of alternative agents. Methods: A pro-
spective pilot study was conducted utilizing daptomycin (6 mg/kg
IV q 24 hours) and cefepime for moderate to high-risk febrile neu-
tropenic patients with increased risk of gram-positive infections.
Eleven patients (10 male, 1 female) were enrolled, ages 40–82 yrs
(mean 5 58). Four patients were post-hematopoietic stem cell
transplant and 7 patients were post-intensive chemotherapy. The
regimen which resulted in defervescence (temperature\ 38C for
48 hours) was continued until ANC . 500 for 4 consecutive days.
Eight patients (73%) successfully completed empiric therapy, with
6 of them (55%) requiring no regimen alteration and 2 of them
(18%) requiring the addition of a broad empiric antifungal. Of
the 3 remaining patients (27%), 2 developed pneumonia and 1
grew an organism resistant to cefepime. Daptomycin was discontin-
ued in each of these 3 patients with appropriate changes made in
coverage. Results: All patients achieved defervescence with
a mean time to defervescence of 3 days (range 5 1–11 days). The
mean duration to resolution of all signs and symptoms of infection
was 3 days. Average length of hospital stay was 10 days (range5 4–
23). At least 4 patients were able to receive the drug on an out pa-
tient basis, reducing their total hospital stay by 1–3 days. There
were no readmissions due to drug failure in the 1-week follow up pe-
riod. There were no ICU admissions, deaths or treatment-limiting
toxicities. The most common non-hematological toxicities were hy-
poalbuminemia, high alkaline phosphatase and mild electrolyte ab-
normalities. Conclusion: Daptomycin could be a safe and effective
alternative to vancomycin in the initial regimen for febrile neutro-
penia. Bactericidal activity and activity against many resistant or-
ganisms may reduce duration of fever and associated outcomes.
Once daily dosing may allow outpatient administration.
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USEFULNESS OF BRONCHOSCOPIC LAVAGE IN INTENSIVE CARE UNIT
FOR CRITICALLY ILL STEM CELL TRANSPLANT RECIPIENTS WITH PUL-
MONARY INFILTRATES
Ghosh, S., Finch, C.G., Champlin, R.E., Kebriaei, P., Giralt, S.A.,
Pravinkumar, S.E. The University of Texas MD Anderson Cancer Cen-
ter, Houston, TX.
Background: Acute hypoxemic respiratory failure (AReF) with
pulmonary infiltrates is the most frequent cause for critical care ad-
missions amongst stem cell transplant (SCT) recipients. Pulmonary
infiltrates in cancer patients are nonspecific and can be caused by in-fection, acute lung injury and also by tumor, radiation and chemo-
therapy. Diagnosis of pulmonary infection by chest x-ray has
a sensitivity of 92% but a specificity of only 33%, rendering mico-
biological diagnosis a challenge. We studied the diagnostic yield
and usefulness of bronchoscopic bronchoalveolar lavage (B-BAL)
in critically-ill SCT recipients. Methods: Following IRB approval,
medical records of critically-ill cancer patients admitted to the on-
cological intensive care unit (ICU), with a clinical suspicion of
pneumonia that underwent B-BAL between 5/1/2006 and 10/30/
2006 were reviewed retrospectively. Recipients of SCT with pulmo-
nary infiltrates and AReF were included in this study. B-BAL sam-
ples were obtained from the radiographic sites of infiltrates and sent
for microbiological analysis. Results: During the six-month study
period, 105 critically-ill adult patients underwent B-BAL of which
20 (19%) were SCT recipients. Sixty percent SCT recipients had
lymphoid and 40% myeloid malignancies. Fifteen patients had re-
ceived allogeneic transplants (unrelated 7, haploidentical 5, siblings
2, cord blood 1) and 5 had autologous transplants. The patients
were a median of 119 days post-SCT (range: 6–1189). Only one pa-
tient had received SCT within the prior 3 weeks. Ninety percent of
SCT recipients had radiographic evidence of pulmonary infiltrates
and were mechanically ventilated. Significant microorganisms were
isolated in 63% cases with identification of bacteria 42%, virus 26%
and fungi 21%. The microbiology and related outcomes are shown
in Table 1. Concurrent infections in extra pulmonary sites were
present in 37% of SCT recipients. Respiratory failure was present
in all patients who died.Conclusion: Positive microbiological yield
was obtained by B-BAL in more than half of SCT recipients admit-
ted to ICU with pulmonary infiltrates. AReF with pulmonary infil-
trates is a serious condition in SCT recipients and B-BAL should be
considered as a useful test, early in the management of critically-ill
SCT recipients with pulmonary infiltrates.
B-BAL Microbiological yield & Outcomes in Critically-ill SCT
Recipients
Microorganisms nBacteria
Coagulase Negative Staphylococcus 3
Xanthomonas Maltophilia 2
Enterococcus spp. 2
Klebsiella pneumoniae 1
Legionella spp. 1
Acenitobacter calcoaceticus-baumannii complex 1
Vancomycin Resistant Enterococcus 1Virus
Parainfluenza 2
Adenovirus 2
Cytomegalovirus Antigen 1Fungus
Candida glabarata 2
Mold (Microsporum and Paecilomyces spp.) 2ICU Outcome
Length of stay in days, median (range) 14 (1–32)
Alive 9 (45%)
Dead 11 (55%)Hospital Outcome
Length of stay in days, median (range) 39 (1–84)
Alive 5 (25%)
Dead 15 (75%)267
LARGER STEM CELL DOSE IS ASSOCIATED WITH DECREASED SYMPTOM
SEVERITY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA
Williams, L.A.1, Giralt, S.A.2, Mendoza, T.R.1, Anderson, K.O.1,
Mobley, G.M.1, Saliba, R.M.2, Qazilbash, M.H.2, Campagnaro, E.L.3,
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